Incyte Gains FDA Acceptance for HS Therapy, Eyes 1H27 Vitiligo Filing
Incyte’s Phase 3 vitiligo data supports a first-half 2027 povorcitinib filing and the FDA has accepted its hidradenitis suppurativa application, potentially creating the first oral anti-inflammatory with up to $1 billion peak sales. New CFO and R&D president hires and EHA trial updates strengthen its late-stage pipeline execution.
1. Positive Phase 3 Vitiligo Results and HS Filing
Incyte reported positive Phase 3 registration study results in adults with nonsegmental vitiligo, supporting a regulatory application expected in the first half of 2027. The FDA also accepted its application for povorcitinib in moderate to severe hidradenitis suppurativa, positioning it as the potential first FDA-approved oral anti-inflammatory for HS with a $500 million to $1 billion peak sales opportunity.
2. Strategic Management Appointments
The company appointed a new Chief Financial Officer and President of Research and Development to strengthen leadership as it advances its late-stage pipeline. These executive hires aim to support commercial launch preparations and oversee critical regulatory submissions and trial completions.
3. EHA and Late-Stage Trial Developments
Incyte detailed substantial upcoming updates for its EHA trial, planning to report data on approximately 100 essential thrombocythemia and 45 myelofibrosis patients to demonstrate durability and tolerability of candidate 989. A randomized Phase 2 study combining Niktimvo with ruxolitinib in first-line chronic graft-versus-host disease is ahead of schedule, with data expected before year-end to guide regulatory strategy.